Levine RJ, et al. Circulating Angiogenic Factors and the Risk of Preeclampsia[J]. New England Journal of Medicine, 2004, 350(7):672.
 Jena MK, et al. Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta[J]. Biomolecules, 2020, 10(6).
 Shen Jing. The diagnostic and predictive value of sFlt-1, PlGF, and sFlt-/PlGF in hypertension during pregnancy[D]. Chinese Academy of Medical Sciences, 2012.
 Kendall RL, et al. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.[J]. Biochem Biophys Res Commun, 1996, 226(2):324-328.
 Clark DE, et al. A Vascular Endothelial Growth Factor Antagonist Is Produced by the Human Placenta and Released into the Maternal Circulation[J]. Biology of Reproduction, 1998, 59(6):1540-8.
 Poon LC, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention[J]. International Journal of Gynecology & Obstetrics. 2019; 145:1-27.
 Kate ED, et al. Placental growth factor testing to access women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedage cluster- randomised controlled trial[J]. Lancet. 2019; 6736(18): 33212-4.
 Zeisler H, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.[J]. N Engl J Med, 2016, 374(1):13-22.
 Duhig KE, et al. Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: A case series study[J]. Acta Obstetricia et Gynecologica Scandinavica. 2020; 00:1-9.
 The Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test and BRAHMS sFlt-1 Kryptor / PlGF plus Kryptor PE ratio to aid the assessment of suspected pre-eclampsia | Guidance and guidelines | NICE[J]. 2016: 1-47.